The Week in Review: March 31, 2017 – April 7, 2017

Friday, April 7, 2017 News Recap Canada Effective April 2017, Alberta Health has expanded access to treatments for hepatitis C in line with what the provinces of British Columbia, Ontario, Saskatchewan, and Québec have just done (Alberta expands drug coverage for hepatitis C patients). As Dr. Shafran, who is clearly worried about continued restrictions, says, “The funders have now opened the doors to let us treat people with mild liver disease … if ...

Scale Up of Hepatitis C Treatment Possible as Brazil Rejects Patent on Key Drug

Decision enables price reductions and scale-up of treatment that leads to cure in 95% of cases Rio de Janeiro, 31 March, 2017 – Treatment for hepatitis C using the key drug sofosbuvir could be vastly scaled up in Brazil after the decision by the National Agency of Health Surveillance (Anvisa) to reject a key patent application on the drug marketed by pharmaceutical corporation Gilead. The decision could pave the way to enable generic competition in Brazil

Hepatitis C drugs re-energize global fight over patents

Lawsuits in India and Argentina seek to reduce drug costs by allowing generic versions of antiviral treatments. The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in those countries. In the 2000s,